GSK2636771 is a potent, orally bioavailable and selective inhibitor ofPI3Kβwith >900-fold selectivity over PI3Kα/PI3Kγ and >10-fold over PI3Kδ. Sensitive to PTEN cell lines. In vitro
GSK-2636771 shows selectively inhibitory activity in PTEN cell lines (human prostate adenocarcinoma PC-3 and breast cancer HCC70) with EC50 of 36 nM and 72 nM, respectively. GSK2636771 significantly decreases cell viability in p110β-reliant PTEN-deficient PC3 prostate and BT549 and HCC70 breast cancer cell lines, and leads to a marked decrease of AKT phosphorylation only in the control prostate and breast cancer cell lines.
In vivo
GSK-2636771 decreases phosphorylated protein kinase Akt (Ser473) levels in these xenograft models. GSK-2636771 (100 mg/kg) do not increase glucose/insulin levels in mice. Cell Data
cell lines:MALME-3M, Colo829, Colo38, A375, SK-MEL28, and A2058 cells